Dabur to submit additional info for its Alwar unit to USFDA

Homegrown FMCG major Dabur today said the USFDA has sought "additional information" for its Alwar unit and the company is "in process of submitting the same".
The company denied that US Food and Drug Administration has put any restriction on import of Dabur's product in market and would not impact its business there, Dabur said in a filing to the BSE.
"USFDA had not put any restriction on import and sale in the US, of products manufactured at Dabur's Alwar unit. The USFDA has, however, sought some additional information and we are in the process of submitting the same.
"This is a routine procedural matter and will not impact our business in the US," the company said, adding that it would have "no material impact on Dabur India".

Dabur manufactures churans and guar gum at its Alwar plant.
The company also said that the issue had no linkages with the recent decline of its share price as it was market driven.
"Decrease in the share price of the company by 5.83 per cent (moving from Rs 273.19 to Rs 257.25) is a market driven and aforesaid news item and has no significant bearing on the same," Dabur said.
The company said this as a response to queries raised by the bourse, which had sought clarification from the company in the wake of some news reports over the USFDA issue.